GENFLEET-B

GenFleet Therapeutics opened down 3.2% in the morning session and continued to weaken, hitting an intraday low of HK$26.62, a decline of 5.3%, before closing at HK$27.22, down 3.2% from the previous close of HK$28.12. The drop was primarily driven by the completion of a placement of 13.6 million new H shares at HK$34.69 each on September 1, representing a ~5.7% discount, which created short-term dilution pressure. The stock fell despite an analyst initiating coverage with a Buy rating, citing GFH276-driven valuation and the emerging RAS franchise. Financially, Q4 revenue slumped 58.55% YoY to HK$23.09 million, net loss widened to HK$609.35 million, with EPS of -HK$1.83 and a net margin of -2639%. The current price of HK$27.22 is well below its 20-day MA of HK$31.06 and 60-day MA of HK$31.28, and is 48.5% off its 52-week high of HK$52.9, though it has still gained 21.8% YTD. However, the company advanced its GFH375 into a Phase II combination trial for pancreatic cancer and a Phase III study for first-line NSCLC, which could provide pipeline catalysts ahead.

劲方医药今日上午盘低开低走，股价从 30.80 港元开盘后持续下探，最终收于 29.20 港元，跌幅 5.19%，完全回吐前一交易日因配股融资消息刺激的涨幅，核心原因在于公司基本面持续承压与市场风险偏好降温的共振。盘中最低触及 29.20 港元，创出日内新低，成交量 29.32 万股，成交额仅 881 万港元，交投清淡反映资金观望情绪浓厚。财报方面，2025 财年第四季度净亏损扩大至 6.09 亿港元，营收同比骤降 58.55% 至 2309 万港元，亏损幅度与营收下滑均超预期，加重了投资者对管线推进速度与现金消耗的担忧。价格位置看，当前股价较 52 周高点 52.90 港元回撤 44.8%，虽年初至今仍录得 30.71% 的涨幅，但已跌破 20 日均线 31.14 港元和 60 日均线 31.35 港元，均线系统形成短期压制。不过，公司近期启动 GFH375 针对 KRAS G12D 突变非小细胞肺癌的 III 期临床试验，并推进全球首个 KRAS 组合疗法在胰腺癌中的 II 期研究，核心管线仍有临床进展支撑。

GenFleet Therapeutics opened sharply higher and traded in a high range, with the morning session high at HK$33.94 as of 09:31 BJ, up 4.95% from the previous close of HK$32.34. The rally was driven by the advancement of its KRAS G12D inhibitor GFH375 into a Phase II first-line study for NSCLC, alongside a recently completed HK$467 million share placement (at HK$34.69 per share) to fund RAS inhibitor trials. However, the company reported a widened net loss of RMB 609 million for the first half of FY2025, with revenue down 58.55% YoY, underscoring persistent fundamental challenges. The stock remains 35.84% below its 52-week high of HK$52.9, but has surged 73% from the 52-week low of HK$19.6, and is trading above both its 20-day (HK$30.76) and 60-day (HK$31.32) moving averages, suggesting near-term technical strength.

GenFleet Therapeutics experienced a volatile intraday session, climbing to a high of HK$35.84 in the morning session before declining steadily in the afternoon to close at HK$32.70, down 4.9%, primarily pressured by the recent completion of a share placement. The company placed 13,600,000 new H-shares at HK$34.69 each, raising net proceeds of over HK$467 million for RAS inhibitor trials, with the current share price now trading below the placement price. Financially, Q4 2025 operating revenue fell 58.55% YoY to HK$23.1 million, while net loss widened to HK$609.4 million, with EPS of -HK$1.83. However, the stock is still up 46.37% year-to-date, well above its MA20 (HK$30.42) and MA60 (HK$31.26), and remains 66.84% above its 52-week low of HK$19.60, reflecting sustained optimism around its KRAS G12D inhibitor GFH375 entering Phase III trials for NSCLC.

GenFleet Therapeutics opened lower at HKD 31.76 in the morning session but surged to an intraday high of HKD 34.10, closing the morning up 4.86% from the previous close of HKD 32.52, with a 7.36% range. The company reported an interim net loss narrowed to RMB 220 million for H1 2026, although revenue dropped to RMB 42.47 million and R&D spending increased. Meanwhile, it initiated a first-in-world Phase II trial of the KRAS G12D inhibitor GFH375 in combination for pancreatic cancer and a Phase III trial for NSCLC in China, signaling robust pipeline progress. However, the latest quarterly report showed EPS loss widened to HKD 1.83 and net loss expanded 401.69% YoY, reflecting ongoing investment phase. At HKD 34.10, the stock is up 52.64% YTD but remains 35.54% below the 52-week high of HKD 52.90, while trading at its 20-day moving average of HKD 34.10 and above the 60-day MA of HKD 31.24.